Serum Insulin-Like Growth Factor Binding Protein 7 as a Potential Biomarker in the Diagnosis and Prognosis of Esophagogastric Junction Adenocarcinoma

Abstract

Background/Aims: Esophagogastric junction adenocarcinoma (EJA) is a malignant tumor associated with high morbidity and has attracted increasing attention due to a rising incidence and low survival rate. Pathological biopsy is the gold standard for diagnosis, but noninvasive and effective tests are lacking, resulting in diagnoses at advanced stages. This study explored the diagnostic value of insulin-like growth factor binding protein 7 (IGFBP7) in EJA. Methods: A total of 120 EJA patients and 88 normal controls were recruited, and their serum levels of IGFBP7 were measured by enzymelinked immunosorbent assay. Receiver operating characteristic (ROC) curve analysis was used to assess the diagnostic value, and Pearson chi-square analysis was used to evaluate the correlation between IGFBP7 and clinical parameters. Kaplan-Meier survival analysis was carried out to assess the effect of IGFBP7 on overall survival (OS). Results: The levels of IGFBP7 were higher in both early-and late-stage EJA patients than in normal controls (p<0.001). The area under the ROC curve for EJA patients was 0.794 (95% confidence interval [CI], 0.733 to 0.854), with a cutoff value of 2.716 ng/mL, a sensitivity of 63.3% (95% CI, 54.0% to 71.8%) and a specificity of 90.9% (95% CI, 82.4% to 95.7%). For the diagnosis of early-stage EJA, the same cutoff value and specificity were obtained, but the sensitivity of IGFBP7 was 54.3% (95% CI, 36.9% to 70.8%). Patients with low IGFBP7 protein expression had lower OS than those with high expression (p=0.034). The multivariate analysis showed that IGFBP7 is an independent prognostic factor for EJA (p=0.011). Conclusions: Serum IGFBP7 acts as a potential diagnostic and prognostic marker for EJA.

<p>Diagnostic Value of Serum Insulin-Like Growth Factor Binding Protein 7 (IGFBP7) in Colorectal Cancer</p>

“…A few studies have explored the potential of serum IGFBP7 as a biomarker for malignant tumors. 20 , 21 , 35 Consistent with the results of this study, high expression of IGFBP7 is positively correlated with cancer. In our previous study, serum IGFBP7 levels were measured by ELISA in 107 normal and 106 ESCC patients.…”

“…A few studies have explored the potential of serum IGFBP7 as a biomarker for malignant tumors. 20,21,35 Consistent with the results of this study, high expression Figure 1 A distribution bar charts of the predicted probability of IGFBP7 in CRC and normal controls. The lowest concentration was 0.26 ng/mL and the highest one was 4.89 ng/mL.…”

“… 20 Another study performed by Liu et al also demonstrated that IGFBP7 provided high diagnostic accuracy with AUCs of 0.800 in EJA and 0.721 in early-stage EJA, respectively. 21 These findings suggested that serum IGFBP7 might be a marker for the diagnosis of gastrointestinal cancer. However, testing serum IGFBP7 alone could not meet the requirements of clinical practice.…”

“…16,17 It has been reported that the expression of IGFBP7 is closely related to cancers such as lung cancer, prostate cancer, esophageal squamous cell carcinoma (ESCC) and esophagogastric junction adenocarcinoma (EJA). [18][19][20][21] However, the relationship between serum IGFBP7 and CRC, especially its diagnostic value, has been rarely reported. This study combines the non-invasive characteristics to explore the diagnostic value of serum IGFBP7 in CRC, with a view to provide an ideal indicator for CRC detection.…”

Serum Insulin-Like Growth Factor Binding Protein 7 for Esophagogastric Junction Adenocarcinoma Diagnosis

“…Liu et al . 1 published an article entitled “Serum insulin-like growth factor binding protein 7 as a potential biomarker in the diagnosis and prognosis of esophagogastric junction adenocarcinoma.” To evaluate the serum insulin-like growth factor binding protein 7 (IGFBP7) reflects for the diagnosis of esophagogastric junction adenocarcinoma (EJA), the investigators collected 120 EJA and 80 healthy controls. Serum IGFBP7 was determined using enzyme-linked immunosorbent assay.…”